Amgen Inc. (AMGN) Stake Increased by Smith Moore & CO.
Smith Moore & CO. increased its position in Amgen Inc. (NASDAQ:AMGN) by 12.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,986 shares of the medical research company’s stock after buying an additional 213 shares during the period. Smith Moore & CO.’s holdings in Amgen were worth $326,000 as of its most recent SEC filing.
A number of other large investors also recently made changes to their positions in AMGN. State of Wisconsin Investment Board boosted its stake in shares of Amgen by 28.1% in the first quarter. State of Wisconsin Investment Board now owns 828,606 shares of the medical research company’s stock worth $135,949,000 after buying an additional 181,810 shares during the last quarter. Holderness Investments Co. boosted its stake in shares of Amgen by 16.6% in the first quarter. Holderness Investments Co. now owns 6,008 shares of the medical research company’s stock worth $986,000 after buying an additional 857 shares during the last quarter. Financial Advisory Service Inc. bought a new stake in shares of Amgen during the first quarter worth about $323,000. Kayne Anderson Rudnick Investment Management LLC boosted its stake in shares of Amgen by 12.8% in the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 31,108 shares of the medical research company’s stock worth $5,104,000 after buying an additional 3,532 shares during the last quarter. Finally, Blue Chip Partners Inc. boosted its stake in shares of Amgen by 8.3% in the first quarter. Blue Chip Partners Inc. now owns 21,462 shares of the medical research company’s stock worth $3,521,000 after buying an additional 1,652 shares during the last quarter. 78.12% of the stock is owned by hedge funds and other institutional investors.
Amgen Inc. (NASDAQ AMGN) traded up 0.81% on Wednesday, reaching $173.63. The company’s stock had a trading volume of 444,025 shares. The company has a market cap of $126.69 billion, a P/E ratio of 15.81 and a beta of 1.35. The company has a 50-day moving average price of $173.53 and a 200 day moving average price of $168.31. Amgen Inc. has a 12 month low of $133.64 and a 12 month high of $184.21.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The company had revenue of $5.81 billion during the quarter, compared to analyst estimates of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the company earned $2.84 earnings per share. On average, equities research analysts anticipate that Amgen Inc. will post $12.57 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Thursday, August 17th will be paid a dividend of $1.15 per share. This represents a $4.60 annualized dividend and a yield of 2.67%. The ex-dividend date of this dividend is Tuesday, August 15th. Amgen’s dividend payout ratio is 41.93%.
COPYRIGHT VIOLATION NOTICE: “Amgen Inc. (AMGN) Stake Increased by Smith Moore & CO.” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.watchlistnews.com/amgen-inc-amgn-stake-increased-by-smith-moore-co/1532150.html.
A number of equities research analysts have issued reports on the company. Cann reaffirmed a “buy” rating on shares of Amgen in a research report on Monday. Mizuho reaffirmed a “buy” rating and set a $183.00 target price (down previously from $195.00) on shares of Amgen in a research report on Monday, August 21st. BidaskClub cut Amgen from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Argus upped their target price on Amgen from $180.00 to $195.00 and gave the stock a “buy” rating in a research report on Thursday, July 27th. Finally, UBS AG set a $180.00 target price on Amgen and gave the stock a “hold” rating in a research report on Wednesday, July 26th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $186.04.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.